文献速递血栓与止血

肝素诱导的血小板减少症管理:系统评价与荟萃分析

Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses.
PubMed 文献 · Blood Adv · 2020-01-01

该研究通过系统评价方法,评估了急性、亚急性及远期肝素诱导的血小板减少症(HIT)管理策略的效果,检索了Medline、EMBASE和Cochrane数据库至2019年7月。纳入研究主要为非比较性研究和病例系列,证据确定性低至极低。非肝素 parenteral 抗凝药与直接口服抗凝药在急性HIT中效果可能无差异;治疗强度抗凝可能优于预防强度;使用下腔静脉滤器或血小板输注可能带来更大危害。

要点

  • 非肝素 parenteral 抗凝药与直接口服抗凝药在急性HIT中效果可能无差异。
  • 治疗强度抗凝可能优于预防强度抗凝。
  • 使用下腔静脉滤器或血小板输注可能带来更大危害。

核心结论

  • 非肝素 parenteral 抗凝药与直接口服抗凝药在急性HIT中效果可能无差异。
  • 治疗强度抗凝的获益可能大于预防强度抗凝。
  • 使用下腔静脉滤器或血小板输注可能导致比不使用这些方法更大的危害。

研究设计与样本

  • 对急性HIT、亚急性HIT A或B及远期HIT患者管理策略效果的系统评价。
  • 检索Medline、EMBASE和Cochrane数据库至2019年7月,纳入已发表的系统评价和原始研究。
  • 两名研究者独立筛选和提取数据,并使用GRADE方法评估证据确定性。

主要发现

  • 纳入研究主要为非比较性研究和病例系列,导致低至极低确定性证据。
  • 非肝素 parenteral 抗凝药与直接口服抗凝药在急性HIT中效果可能无差异。
  • 治疗强度抗凝的获益可能大于预防强度抗凝。
  • 使用下腔静脉滤器或血小板输注可能导致比不使用这些方法更大的危害。
  • 特殊情况下(如心血管干预或肾脏替代治疗)管理证据的确定性也为低至极低。

临床怎么用

  • 在急性HIT中,非肝素 parenteral 抗凝药与直接口服抗凝药的选择可能无差异。
  • 考虑使用治疗强度而非预防强度抗凝。
  • 避免使用下腔静脉滤器或血小板输注,因其可能带来更大危害。

局限性

  • 主要纳入非比较性研究和病例系列,证据确定性低至极低。
  • 需要额外研究评估非肝素抗凝药,并优先开发减少血栓形成而不增加出血的新疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin-induced thrombocytopenia (HIT) is a prothrombotic adverse drug reaction occurring in <0.1% to 7% of patients receiving heparin products depending on the patient population and type of heparin. Management of HIT is highly dependent on a sequence of tests for which clinicians may or may not have the results when care decisions need to be made. We conducted systematic reviews of the effects of management strategies in persons with acute HIT, subacute HIT A or B, and remote HIT. We searched Medline, EMBASE, and the Cochrane Database through July 2019 for previously published systematic reviews and primary studies. Two investigators independently screened and extracted data and assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. We found primarily noncomparative studies and case series assessing effects of treatments, which led to low to very low certainty evidence. There may be little to no difference in the effects between nonheparin parenteral anticoagulants and direct oral anticoagulants in acute HIT. The benefits of therapeutic-intensity may be greater than prophylactic-intensity anticoagulation. Using inferior vena cava filters or platelet transfusion may result in greater harm than not using these approaches. Evidence for management in special situations, such as for patients undergoing cardiovascular interventions or renal replacement therapy, was also low to very low certainty. Additional research to evaluate nonheparin anticoagulants is urgently needed, and the development of novel treatments that reduce thrombosis without increasing hemorrhage should be a priority.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Morgan RL, Ashoorion V, Cuker A, et al. Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses. Blood Adv. 2020. PMID: 33095876. doi:10.1182/bloodadvances.2020002963

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。